Vir Biotechnology’s (NYSE:VIR) quiet period will end on Wednesday, November 20th. Vir Biotechnology had issued 7,142,858 shares in its IPO on October 11th. The total size of the offering was $142,857,160 based on an initial share price of $20.00. During the company’s quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Several analysts recently commented on the stock. Cowen assumed coverage on shares of Vir Biotechnology in a report on Tuesday, November 5th. They set an “outperform” rating for the company. Goldman Sachs Group assumed coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They issued a “buy” rating and a $37.00 target price for the company. JPMorgan Chase & Co. assumed coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $25.00 target price for the company. Finally, Barclays assumed coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $25.00 target price for the company.

NYSE VIR opened at $13.15 on Wednesday. Vir Biotechnology has a 12-month low of $13.07 and a 12-month high of $16.50.

In other Vir Biotechnology news, insider Abu Dhabi Investment Authority bought 1,000,000 shares of Vir Biotechnology stock in a transaction on Wednesday, October 16th. The stock was purchased at an average cost of $14.41 per share, for a total transaction of $14,410,000.00. Also, major shareholder Endurance (Cayman) Ltd Svf bought 950,000 shares of Vir Biotechnology stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of $14.22 per share, with a total value of $13,509,000.00.

About Vir Biotechnology

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Featured Article: Special Dividends

Source